In 2026, Tirzepatide stands as a leading dual GIP/GLP-1 receptor agonist, approved under brand names like Mounjaro for type 2 diabetes management and Zepbound for chronic weight reduction in adults with obesity or overweight plus weight-related conditions. This once-weekly injectable medication delivers substantial glycemic control and body weight loss—often 15-20% or more in clinical settings—by […]